Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2022
Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus
Nat Med. 2022;28(10):2124–2132 doi: 10.1038/s41591-022-02017-5
Data suggest that CD19 chimeric antigen receptor (CAR) T cell transfer is feasible, tolerable and highly effective in patients with SLE.
Keywords:
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
N Engl J Med. 2022;387(10):894–904 doi: 10.1056/NEJMoa2118025
Phase 2 study, in patients with systemic lupus erythematosus, shows that litifilimab is associated with a greater reduction from baseline in the number of swollen and tender joints than placebo, over a period of 24 weeks.
October 2022
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188
Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.
June 2022
Biological impact of iberdomide in patients with active systemic lupus erythematosus
doi: 10.1136/annrheumdis-2022-222212
Phase 2b study evaluating the pharmacodynamics and pharmacokinetics of oral iberdomide in patients with active SLE demonstrates that iberdomide significantly improves lupus disease activity and reduces hallmarks of the immunopathogenesis of SLE.
Keywords:
March 2022
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus
Kidney Int Rep. 2021;7(3):516-525 doi: 10.1056/NEJMoa2106535
This Phase 2 trial evaluated iberdomide in patients with moderate-to-severe systemic lupus erythematosus (SLE).
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
Ann Rheum Dis. 2022;81(4):496–506 doi: 10.1136/annrheumdis-2021-221478
Despite not meeting the primary endpoint, this Phase II trial of anifrolumab in patients with active lupus nephritis (LN) demonstrates that anifrolumab IR is associated with numerical improvements over placebo across endpoints – including complete renal response – in patients with active LN.
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab
Lancet Rheumatol 2022;4:e198–207
In patients with moderate-to-severe SLE, British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responders report improvements in disease activity, health-related quality of life, fatigue, and pain.
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
Kidney Int. 2022;101(2):403-413 doi: 10.1016/j.kint.2021.08.027
Post-hoc analysis data suggests that the addition of belimumab to standard therapy may be effective in preserving long-term kidney function in patients with lupus nephritis (LN).
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
Lancet Rheumatol. Published online February 3, 2022
Across two pivotal phase 3 trials (TULIP-1 and TULIP-2), anifrolumab treatment improved systemic lupus erythematosus (SLE) disease activity across multiple organ domains, compared with placebo.
Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keab883
Easy-BILAG is a high-accuracy, time-efficient tool for recording BILAG-2004 disease activity in systemic lupus erythematosus (SLE).
Disease activity measurements in SLE are necessary for optimal patient care, treat-to-target approaches and clinical guidelines. However, administrative burden and potential frequency of errors with the current comprehensive disease activity instrument (BILAG-2004) limits its use in routine practice.